A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
JAMA Psychiatry March 1, 2017 Gerard Sanacora, Mark A. Frye, William M. Mcdonald et al. 577 citations
Ketamine can produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. However, existing studies have relatively small sample sizes, lack longer-term data on efficacy, and provide limited data on safety. Despite these limitations, ketamine is increasingly used off-label for mood and other psychiatric disorders. This review and consensus statement provides an overview of the data, highlights limitations, and offers suggestions to facilitate evidence-based clinical decision-making and patient safety.